Oncview


Advances in Multiple Myeloma: Insights on Translating Evidence to Clinical Practice

May 19th 2022

Dr Rafael Fonseca presents an overview of recent updates in the treatment of multiple myeloma and discusses strategies for incorporating the evidence into clinical practice.

Treatment Options for Early-Stage HER2+ Breast Cancer

May 6th 2022

Sarah M. Tolaney, MD, MPH, discusses the range of treatment options for early-stage HER2+ breast cancer, including subcutaneous options and investigational therapies.

Advances in Systemic Therapy of Differentiated Thyroid Cancer in Second Line and Beyond

March 30th 2022

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including treatment options that are currently available, as well as sharing insights on emerging therapies.

Metastatic Renal Cell Carcinoma: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management

March 22nd 2022

This OncView program features content experts who share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and comment on emerging data in the field.

Advances in Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease (GvHD)

March 4th 2022

An expert in hematology/oncology, Dr Yi-Bin Chen, provides insight on chronic GvHD, with a focus on early detection of disease and therapeutic options for the management of steroid-refractory chronic GvHD.

Treatment Options for Early-Stage HER2-Positive Breast Cancer

February 15th 2022

Virginia Kaklamani, MD, DSc, provides a discussion on the frontline and maintenance therapies available for the management of early-stage HER2+ breast cancer.

EGFR Exon 20 Insertion As A Therapeutic Target in Non-small Cell Lung Cancer

November 18th 2021

A leading expert in lung cancer provides insights on recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.

Recent Updates in Treatment of Non-Metastatic Castration Resistant Prostate Cancer

November 16th 2021

Dr Aaron Berger discusses recent advances in treatment and management of patients with nonmetastatic castrate-resistant prostate cancer.

Immunotherapy Response Monitoring in Lung Cancer

October 18th 2021

Roy S. Herbst, MD, PhD, reviews currently available treatment options in immunotherapy in non-small-cell lung cancer and approaches to monitoring treatment response.

PARP Inhibitors in Prostate Cancer

October 15th 2021

Part 1: Oliver Sartor, MD, gives an overview of the use of PARP inhibitors to treat metastatic castration-resistant prostate cancer.

Part 2: Alicia Morgans, MD, MPH, discuses the importance of PARP inhibitors in the treatment of metastatic prostate cancer, as well as castration-resistant prostate cancer.